036480 — Daesung Microbiological Labs Co Balance Sheet
0.000.00%
- KR₩28bn
- KR₩39bn
- KR₩24bn
Annual balance sheet for Daesung Microbiological Labs Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 10,052 | 9,935 | 12,859 | 11,727 | 9,053 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3,892 | 3,114 | 3,251 | 4,285 | 3,958 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 23,757 | 23,722 | 28,690 | 28,717 | 23,641 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 35,285 | 35,846 | 33,303 | 32,124 | 31,944 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 62,263 | 62,620 | 65,109 | 64,290 | 58,379 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4,578 | 5,315 | 10,611 | 10,398 | 4,530 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 25,952 | 25,616 | 26,272 | 26,942 | 23,230 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 36,311 | 37,004 | 38,837 | 37,349 | 35,149 |
| Total Liabilities & Shareholders' Equity | 62,263 | 62,620 | 65,109 | 64,290 | 58,379 |
| Total Common Shares Outstanding |